Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02102490 · ClinicalTrials.gov registry record · Phase 2
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
NCT02102490 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 132 participants.
The verdict
NCT02102490, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate whether the study drug known as abemaciclib is effective in treating participants with breast cancer who have already tried other drug treatments.
Interventions
- DRUG Abemaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2014-06-10 |
| Est. Completion | 2018-10-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02102490
The ClinicalTrials.gov registry entry for NCT02102490 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abemaciclib is the first listed.
NCT02102490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02102490 about?
NCT02102490 is a clinical study titled "A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread". The main purpose of this study is to evaluate whether the study drug known as abemaciclib is effective in treating participants with breast cancer who have already tried other drug treatments.
What is the current status of trial NCT02102490?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2014-06-10. Estimated completion is 2018-10-22.
What interventions are being tested in trial NCT02102490?
The interventions under investigation include: Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT02102490?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.